Search

Pharma Mar SA

Gesloten

73.9 -3.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

73.55

Max

74

Belangrijke statistieken

By Trading Economics

Inkomsten

27M

23M

Verkoop

18M

56M

K/W

Sectorgemiddelde

32.604

37.461

EPS

1.33

Dividendrendement

1.01

Winstmarge

41.41

Werknemers

500

EBITDA

27M

26M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+61.51% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.01%

2.33%

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-86M

1.4B

Vorige openingsprijs

77.05

Vorige sluitingsprijs

73.9

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Pharma Mar SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 18:41 UTC

Winsten

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 okt 2025, 18:31 UTC

Winsten

Correction to Procter & Gamble to Focus on Innovation

24 okt 2025, 16:25 UTC

Belangrijke Marktbewegers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 okt 2025, 21:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 okt 2025, 21:24 UTC

Marktinformatie

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 okt 2025, 21:07 UTC

Winsten

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 okt 2025, 20:58 UTC

Winsten

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 20:40 UTC

Winsten

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 okt 2025, 20:24 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:23 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:13 UTC

Winsten

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 20:07 UTC

Marktinformatie

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 okt 2025, 19:40 UTC

Marktinformatie

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 okt 2025, 19:35 UTC

Marktinformatie

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 okt 2025, 19:33 UTC

Winsten

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 okt 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 okt 2025, 18:52 UTC

Winsten

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:41 UTC

Winsten

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:03 UTC

Winsten

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 okt 2025, 18:02 UTC

Winsten

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 okt 2025, 18:00 UTC

Marktinformatie

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 okt 2025, 16:57 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 okt 2025, 16:54 UTC

Marktinformatie

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 okt 2025, 16:44 UTC

Marktinformatie
Winsten

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 okt 2025, 16:39 UTC

Marktinformatie
Winsten

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 okt 2025, 16:33 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:23 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 16:07 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Pharma Mar SA Prognose

Koersdoel

By TipRanks

61.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 120.002 EUR  61.51%

Hoogste 120 EUR

Laagste 120 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pharma Mar SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

72.75 / 74.3Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
help-icon Live chat